JPWO2022020105A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022020105A5 JPWO2022020105A5 JP2023504620A JP2023504620A JPWO2022020105A5 JP WO2022020105 A5 JPWO2022020105 A5 JP WO2022020105A5 JP 2023504620 A JP2023504620 A JP 2023504620A JP 2023504620 A JP2023504620 A JP 2023504620A JP WO2022020105 A5 JPWO2022020105 A5 JP WO2022020105A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- complex
- conjugate
- composition
- molecular payload
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063055721P | 2020-07-23 | 2020-07-23 | |
| US63/055,721 | 2020-07-23 | ||
| US202063069071P | 2020-08-23 | 2020-08-23 | |
| US63/069,071 | 2020-08-23 | ||
| US202163143825P | 2021-01-30 | 2021-01-30 | |
| US63/143,825 | 2021-01-30 | ||
| PCT/US2021/040984 WO2022020105A1 (en) | 2020-07-23 | 2021-07-09 | Anti-transferrin receptor (tfr) antibody and uses thereof |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2023535443A JP2023535443A (ja) | 2023-08-17 |
| JP2023535443A5 JP2023535443A5 (https=) | 2024-07-17 |
| JPWO2022020105A5 true JPWO2022020105A5 (https=) | 2024-07-17 |
| JP7803925B2 JP7803925B2 (ja) | 2026-01-21 |
Family
ID=79729848
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023504620A Active JP7803925B2 (ja) | 2020-07-23 | 2021-07-09 | 抗トランスフェリン受容体（ＴｆＲ）抗体およびその使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230256112A1 (https=) |
| EP (1) | EP4185315A4 (https=) |
| JP (1) | JP7803925B2 (https=) |
| KR (1) | KR20230041760A (https=) |
| CN (1) | CN116348138A (https=) |
| AU (1) | AU2021312708A1 (https=) |
| BR (1) | BR112023001005A2 (https=) |
| CA (1) | CA3186727A1 (https=) |
| IL (1) | IL299667A (https=) |
| MX (1) | MX2023000962A (https=) |
| WO (1) | WO2022020105A1 (https=) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12370264B1 (en) | 2018-08-02 | 2025-07-29 | Dyne Therapeutics, Inc. | Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering oligonucleotide to a subject |
| US11911484B2 (en) | 2018-08-02 | 2024-02-27 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| US12097263B2 (en) | 2018-08-02 | 2024-09-24 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| EP3829595A4 (en) | 2018-08-02 | 2022-08-24 | Dyne Therapeutics, Inc. | MUSCLE-DIRECTED COMPLEXES AND USES THEREOF IN THE TREATMENT OF DYSTROPHINOPATHIES |
| US11168141B2 (en) | 2018-08-02 | 2021-11-09 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| US12018087B2 (en) | 2018-08-02 | 2024-06-25 | Dyne Therapeutics, Inc. | Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject |
| US20220193250A1 (en) | 2018-08-02 | 2022-06-23 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
| KR20230044242A (ko) * | 2020-07-23 | 2023-04-03 | 다인 세라퓨틱스, 인크. | 근육 표적화 복합체 및 디스트로핀병증을 치료하기 위한 그의 용도 |
| WO2022020108A1 (en) * | 2020-07-23 | 2022-01-27 | Dyne Therapeutics, Inc. | Muscle-targeting complexes and uses thereof |
| US11672872B2 (en) | 2021-07-09 | 2023-06-13 | Dyne Therapeutics, Inc. | Anti-transferrin receptor antibody and uses thereof |
| US11638761B2 (en) | 2021-07-09 | 2023-05-02 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy |
| US11771776B2 (en) | 2021-07-09 | 2023-10-03 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| IL309936A (en) * | 2021-07-09 | 2024-03-01 | Dyne Therapeutics Inc | Muscle targeting complexes and formulations for the treatment of dystrophinopathy |
| US11633498B2 (en) | 2021-07-09 | 2023-04-25 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| US11969475B2 (en) | 2021-07-09 | 2024-04-30 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
| EP4396231A1 (en) | 2021-09-01 | 2024-07-10 | Biogen MA Inc. | Anti-transferrin receptor antibodies and uses thereof |
| US20250339553A1 (en) | 2022-04-15 | 2025-11-06 | Dyne Therapeutics, Inc. | Muscle targeting complexes and formulations for treating myotonic dystrophy |
| IL318625A (en) * | 2022-07-29 | 2025-03-01 | Regeneron Pharma | Compositions and methods for transferrin receptor (TFR)-mediated delivery to brain and muscle |
| US20260015409A1 (en) * | 2022-09-20 | 2026-01-15 | Dana-Farber Cancer Institute, Inc. | Receptor-mediated endocytosis for targeted internalization and degradation of membrane proteins and cargos |
| AU2024299328A1 (en) | 2023-07-21 | 2026-01-22 | Marrow Therapeutics, Inc. | Hematopoietic cell targeting conjugates and related methods |
| WO2025090898A1 (en) * | 2023-10-26 | 2025-05-01 | Biogen Ma Inc. | Anti-transferrin receptor antibodies and uses thereof cross reference to related applications |
| WO2025140522A1 (en) * | 2023-12-29 | 2025-07-03 | Nona Biosciences (Suzhou) Co., Ltd. | Anti-tfr1 antibodies, preparation methods and uses thereof |
| CN119161483B (zh) * | 2024-10-16 | 2026-02-06 | 中国人民解放军军事科学院军事医学研究院 | 人源抗转铁蛋白受体1抗体及其应用 |
| CN119192378B (zh) * | 2024-10-16 | 2025-10-17 | 中国人民解放军军事科学院军事医学研究院 | 一种pH敏感型人源抗转铁蛋白受体1抗体 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011130164A2 (en) * | 2010-04-13 | 2011-10-20 | The Regents Of The University Of California | Unconjugated anti-tfr antibodies and compositions thereof for the treatment of cancer |
| WO2014189973A2 (en) * | 2013-05-20 | 2014-11-27 | Genentech, Inc. | Anti-transferrin receptor antibodies and methods of use |
| TWI769982B (zh) | 2015-06-24 | 2022-07-11 | 日商Ｊｃｒ製藥股份有限公司 | 通過血腦障壁之抗人類運鐵蛋白受體抗體 |
| FR3049951A1 (fr) * | 2016-04-12 | 2017-10-13 | Univ Rabelais Francois | Nouvelles constructions peptidiques et leur utilisation dans le traitement de la toxoplasmose |
| AR126019A1 (es) * | 2018-05-30 | 2023-09-06 | Novartis Ag | Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación |
| CN112930193A (zh) | 2018-08-02 | 2021-06-08 | 达因疗法公司 | 肌肉靶向复合物及其在治疗肌肉萎缩中的用途 |
| WO2020028842A1 (en) | 2018-08-02 | 2020-02-06 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating hypertrophic cardiomyopathy |
| IL312067B2 (en) * | 2018-12-21 | 2025-08-01 | Avidity Biosciences Inc | Anti-transferrin receptor antibodies and uses thereof |
-
2021
- 2021-07-09 CN CN202180064690.5A patent/CN116348138A/zh active Pending
- 2021-07-09 AU AU2021312708A patent/AU2021312708A1/en active Pending
- 2021-07-09 US US18/017,167 patent/US20230256112A1/en active Pending
- 2021-07-09 CA CA3186727A patent/CA3186727A1/en active Pending
- 2021-07-09 BR BR112023001005A patent/BR112023001005A2/pt unknown
- 2021-07-09 IL IL299667A patent/IL299667A/en unknown
- 2021-07-09 KR KR1020237005829A patent/KR20230041760A/ko active Pending
- 2021-07-09 JP JP2023504620A patent/JP7803925B2/ja active Active
- 2021-07-09 EP EP21846109.3A patent/EP4185315A4/en active Pending
- 2021-07-09 WO PCT/US2021/040984 patent/WO2022020105A1/en not_active Ceased
- 2021-07-09 MX MX2023000962A patent/MX2023000962A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2022020105A5 (https=) | ||
| JP7447183B2 (ja) | 親水性抗体－薬物コンジュゲート | |
| US12121527B2 (en) | Anthracycline-based antibody drug conjugates having high in vivo tolerability | |
| US20230073692A1 (en) | Anti-slc34a2 antibodies, antibody drug conjugates, and methods of use thereof | |
| JPWO2021154476A5 (https=) | ||
| JP2008515889A5 (https=) | ||
| JP2015526435A (ja) | 抗体成分と血液脳関門を通過するポリペプチドと細胞毒とを含むコンジュゲート | |
| CN108452319A (zh) | 靶向cd20的抗体偶联药物制剂 | |
| US20110142756A1 (en) | Method And Composition For The Treatment Of Cancer By The Enzymatic Conversion Of Soluble Radioactive Toxic Precipitates In The Cancer | |
| TW202330040A (zh) | 抗ｈｅｒ２抗體藥物偶聯物和酪胺酸激酶抑制劑聯合在製備治療腫瘤的藥物中的用途 | |
| JP2026505129A (ja) | 抗ｃｄｈ１７抗体及びその使用 | |
| CN109414509B (zh) | 使用双特异性抗体的抗体药物偶联物平台 | |
| IL310175A (en) | Methods for treating non-muscle invasive bladder cancer (NMIBC) with antibody-drug conjugates (ADC) that bind to 191P4D12 proteins | |
| JP2022514348A (ja) | チオール多重リンカーを有するａｄｃ | |
| WO2022206881A1 (zh) | 核酸自组装介导的adc药物的构建方法及应用 | |
| Shao et al. | Inhibition of human tumor xenograft growth in nude mice by a conjugate of monoclonal antibody LA22 to epidermal growth factor receptor with anti-tumor antibiotics mitomycin C | |
| CN101277716A (zh) | 治疗癌症的抗体 | |
| US7615221B2 (en) | Compositions and methods for treating cancer | |
| US20230346969A1 (en) | Intermediate for preparing antibody-drug conjugate (adc), preparation method therefor, and use thereof | |
| CN114667160A (zh) | 免疫耐受的弹性蛋白样重组肽及其使用方法 | |
| Yu et al. | The antibody-drug conjugate GENA-111 conjugated to auristatin F shows therapeutic potency in BCAM positive epithelial cancer | |
| CN119868576A (zh) | 用于制备抗体与药物偶联物的中间体及其制备方法和应用 | |
| WO2025176180A1 (zh) | 艾日布林衍生物药物偶联物用于治疗肿瘤的用途 | |
| HK40088389A (zh) | 针对folr1的双特异性抗体及其用途 | |
| HK40088389B (zh) | 针对folr1的双特异性抗体及其用途 |